The Intuitive Surgical story
What drives Intuitive Surgical, what its price assumes and what could change the story, written from its own filings.
- Procedures drive recurring revenue. Instruments and accessories generated $1.80 billion in the quarter to September 2026, supported by approximately 14% growth in da Vinci procedures and approximately 31% growth in Ion procedures.
- Growth met a charge. Revenue rose 22% in the quarter to September 2026, but a $450 million proposed antitrust settlement charge helped push net income below the prior-year quarter.
- Cash expectations are substantial. At $438.00 per share, the price implies free cash flow after stock pay growing 23.5% a year for ten years, compared with 4.8% annually over the last 10 years.
